Literature DB >> 22331093

Clinical potential of the ERG oncoprotein in prostate cancer.

Philip Rosen1, Isabell A Sesterhenn, Stephen A Brassell, David G McLeod, Shiv Srivastava, Albert Dobi.   

Abstract

Oncogenic activation of ERG resulting from gene fusion is present in over half of all patients with prostate cancer in Western countries. Although the underlying genetic mechanisms have been extensively studied, evaluation of the ERG oncoprotein--the translational product of ERG gene fusions--has just begun. The robust correlation between ERG oncoprotein detection and gene fusion status enables rapid characterization of this protein in large patient cohorts. Recent studies have focused on characterizing the ERG oncoprotein and determining its potential role in the diagnosis and biological stratification of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22331093     DOI： 10.1038/nrurol.2012.10

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  76 in total

1.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Authors:  Veit J Scheble; Martin Braun; Rameen Beroukhim; Craig H Mermel; Christian Ruiz; Theresia Wilbertz; Ann-Cathrin Stiedl; Karen Petersen; Markus Reischl; Rainer Kuefer; David Schilling; Falko Fend; Glen Kristiansen; Matthew Meyerson; Mark A Rubin; Lukas Bubendorf; Sven Perner
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

2.  Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Claudia D Baldus; Amy S Ruppert; Michael D Radmacher; Krzysztof Mrózek; Susan P Whitman; Jonathan E Kolitz; Colin G Edwards; James W Vardiman; Bayard L Powell; Maria R Baer; Joseph O Moore; Danilo Perrotti; Michael A Caligiuri; Andrew J Carroll; Richard A Larson; Albert de la Chapelle; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

3.  Single focus prostate cancer: pathological features and ERG fusion status.

Authors:  Sara M Falzarano; Ming Zhou; Adrian V Hernandez; Eric A Klein; Mark A Rubin; Cristina Magi-Galluzzi
Journal:  J Urol       Date:  2010-12-17       Impact factor: 7.450

4.  Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript.

Authors:  X T Kong; K Ida; H Ichikawa; K Shimizu; M Ohki; N Maseki; Y Kaneko; M Sako; Y Kobayashi; A Tojou; I Miura; H Kakuda; T Funabiki; K Horibe; H Hamaguchi; Y Akiyama; F Bessho; M Yanagisawa; Y Hayashi
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

5.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Authors:  Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

6.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate.

Authors:  J Clark; G Attard; S Jhavar; P Flohr; A Reid; J De-Bono; R Eeles; P Scardino; J Cuzick; G Fisher; M D Parker; C S Foster; D Berney; G Kovacs; C S Cooper
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

7.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Authors:  Dorothee Pflueger; David S Rickman; Andrea Sboner; Sven Perner; Christopher J LaFargue; Maria A Svensson; Benjamin J Moss; Naoki Kitabayashi; Yihang Pan; Alexandre de la Taille; Rainer Kuefer; Ashutosh K Tewari; Francesca Demichelis; Mark S Chee; Mark B Gerstein; Mark A Rubin
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

8.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

9.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

10.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Authors:  Anuradha Gopalan; Margaret A Leversha; Jaya M Satagopan; Qin Zhou; Hikmat A Al-Ahmadie; Samson W Fine; James A Eastham; Peter T Scardino; Howard I Scher; Satish K Tickoo; Victor E Reuter; William L Gerald
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701
View more
  28 in total

1.  [Personalized urooncology based on molecular uropathology: what is the future?].

Authors:  E Dahl; F Haller
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

2.  TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.

Authors:  Ömer Yılmaz; Ufuk Berber; Sezgin Okçelik; Hasan Soydan; Ferhat Ateş; Kenan Karademir
Journal:  Turk J Urol       Date:  2016-06

Review 3.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

4.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

Review 5.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

Review 6.  Analysis of Tumor Biology to Advance Cancer Health Disparity Research.

Authors:  Cheryl J Smith; Tsion Z Minas; Stefan Ambs
Journal:  Am J Pathol       Date:  2017-11-11       Impact factor: 4.307

7.  Predominance of ERG-negative high-grade prostate cancers in African American men.

Authors:  James Farrell; Denise Young; Yongmei Chen; Jennifer Cullen; Inger L Rosner; Jacob Kagan; Sudhir Srivastava; David G McLEOD; Isabell A Sesterhenn; Shiv Srivastava; Gyorgy Petrovics
Journal:  Mol Clin Oncol       Date:  2014-08-07

8.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

9.  ERG expression in epithelioid sarcoma: a diagnostic pitfall.

Authors:  Markku Miettinen; Zengfeng Wang; Maarit Sarlomo-Rikala; Ziedulla Abdullaev; Svetlana D Pack; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

10.  Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.

Authors:  A Marcell Szász; Attila Majoros; Philip Rosen; Shiv Srivastava; Albert Dobi; Attila Szendrői; Janina Kulka; Péter Nyirády
Journal:  Int Urol Nephrol       Date:  2013-05-18       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.